Literature DB >> 21551158

XMRV, prostate cancer and chronic fatigue syndrome.

Julia C Kenyon1, Andrew M L Lever.   

Abstract

BACKGROUND: A new retrovirus, xenotropic murine leukaemia virus-related virus (XMRV), was identified in 2006 and an association was claimed between it and a genetic polymorphism predisposing to cancer of the prostate. In 2009 the same virus was identified in a cohort of patients with chronic fatigue syndrome (CFS). In 2010 a second related virus was identified in a separate group of CFS patients. A series of studies from disparate geographical areas have failed to substantiate this work. Most recently several papers have suggested that the detection of these viruses was explained by laboratory contamination. SOURCES OF DATA: All papers including the wording XMRV were abstracted from the NIH library of medicine database and included in the analysis. AREAS OF AGREEMENT: XMRV is a newly described retrovirus whose nucleic acid has been identified in samples from patients with both prostate cancer and CFS. AREAS OF CONTROVERSY: Opinions differ as to whether the detected nucleic acid indicates infection with this virus in this disease or whether laboratory contamination of samples accounts for its presence. GROWING POINTS: An increasing number of papers now refute the association of XMRV with human disease in humans although there is some evidence of serological reactivity to the virus. While it is unlikely that XMRV is a major cause of either prostate cancer or CFS, it can infect human cells and might yet have a role in human disease. AREAS TIMELY FOR DEVELOPING RESEARCH: Further studies to either prove or disprove the disease association of the virus are ongoing.

Entities:  

Mesh:

Year:  2011        PMID: 21551158     DOI: 10.1093/bmb/ldr010

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  7 in total

1.  No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses.

Authors:  Harriet C T Groom; Anne Y Warren; David E Neal; Kate N Bishop
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

2.  Identification of XMRV infection-associated microRNAs in four cell types in culture.

Authors:  Ketha V K Mohan; Krishnakumar Devadas; Shilpakala Sainath Rao; Indira Hewlett; Chintamani Atreya
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

3.  No biological evidence of XMRV infection in cervical smears from HIV/ HPV positive and negative Kenyan women.

Authors:  Xiaotong He; Thomas D J Walker; Innocent O Maranga; Anthony W Oliver; Lynne Hampson; Ian N Hampson
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

4.  No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome.

Authors:  Imke Steffen; D Lorne Tyrrell; Eleanor Stein; Leilani Montalvo; Tzong-Hae Lee; Yanchen Zhou; Kai Lu; William M Switzer; Shaohua Tang; Hongwei Jia; Darren Hockman; Deanna M Santer; Michael Logan; Amir Landi; John Law; Michael Houghton; Graham Simmons
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

5.  Utilization of replication-competent XMRV reporter-viruses reveals severe viral restriction in primary human cells.

Authors:  Christina Martina Stürzel; David Palesch; Mohammad Khalid; Silke Wissing; Nicole Fischer; Jan Münch
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

Review 6.  The clinical value of cytokines in chronic fatigue syndrome.

Authors:  Tiansong Yang; Yan Yang; Delong Wang; Chaoran Li; Yuanyuan Qu; Jing Guo; Tianyu Shi; Wang Bo; Zhongren Sun; Tetsuya Asakawa
Journal:  J Transl Med       Date:  2019-06-28       Impact factor: 5.531

7.  XMRV induces cell migration, cytokine expression and tumor angiogenesis: are 22Rv1 cells a suitable prostate cancer model?

Authors:  Kristin Stieler; Udo Schumacher; Andrea Kristina Horst; Nicole Fischer
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.